Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2008
10/07/2008CA2264287C A process for producing solid dosage forms
10/07/2008CA2250219C Materials and methods for making improved liposome compositions
10/07/2008CA2237306C Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
10/07/2008CA2127317C Method of producing sustained-release preparation
10/02/2008WO2008118752A2 Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
10/02/2008WO2008118096A1 Carriers for drug delivery
10/02/2008WO2008118093A1 Fusion protein capable of degrading amyloid beta peptide
10/02/2008WO2008118013A2 Targeted intracellular delivery of antiviral agents
10/02/2008WO2008117828A1 Prompt nucleic acid delivery carrier composition
10/02/2008WO2008117814A1 Oral pharmaceutical preparation for colon-specific delivery
10/02/2008WO2008117746A1 Solid fibrinogen preparation
10/02/2008WO2008117682A1 Non-animal derived soft capsule shell and soft capsule having the same
10/02/2008WO2008117646A1 Method for stabilization of antibody
10/02/2008WO2008117125A2 Compositions capable of facilitating penetration across a biological barrier
10/02/2008WO2008116913A2 Peptide compounds with transient biodegradable pegylation
10/02/2008WO2008116614A1 Mucosal bioadhesive slow release carrier for delivering active principles
10/02/2008WO2008116468A2 Mhc peptide complexes and uses thereof in infectious diseases
10/02/2008WO2008116316A1 Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
10/02/2008WO2008116299A1 Cancer disease modifying antibody 010207-01 produced by hybridoma cell line ar51a630.3.
10/02/2008WO2008116293A1 Multivalent heterobifunctional polymers and methods of their use
10/02/2008WO2008082948A3 Ophthalmic alginate composition related methods of manufacture and methods of use
10/02/2008WO2008070402A3 Intraocular drug delivery systems
10/02/2008WO2008039254A3 Rna nanoparticles and nanotubes
10/02/2008WO2007140371A8 Antibodies and immunoconjugates and uses therefor
10/02/2008WO2007127158A3 Modification of percutaneous absorption of topically active materials
10/02/2008WO2007101400A8 Transdermal patch containing rasagiline for treatment or prophylaxis of nervous system disease and its preparation process
10/02/2008WO2007093806A8 Dissolution aids for oral peptide delivery comprising a biguanide
10/02/2008WO2005079490A3 Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
10/02/2008US20080243043 Acrylic polymers of a non-primary hydroxyl functional monomer and low glass transition temperature alkyl acrylate monomers are useful in adhesive tape, plaster, or bandages; e.g., butyl acrylate-tert-octylacrylamide-hydroxyethyl acrylate-acrylic acid tetrapolymer; transdermal drug delivery
10/02/2008US20080242843 Function of a haptoglobin-haemoglobin receptor and the uses thereof
10/02/2008US20080242741 Intranasal drug delivery system
10/02/2008US20080242740 Aroma compositions of alkamides with hesperetin and/or 4-hydroxydihydrochalcones and salts thereof for enhancing sweet sensory impressions
10/02/2008US20080242739 Mixed hydrophobe polysaccharide as polymeric emulsifier and stabilizer
10/02/2008US20080242738 for cells, proteins, DNA or other molecules encapsulation; carragenan, chitosan, hyaluronic acid, cellulose or alginate; with thiophene, aniline or pyrrole polymerizable moiety grafted on
10/02/2008US20080242737 Packaged oral delivery system containing a complexate
10/02/2008US20080242736 Packaged film dosage unit containing a complexate
10/02/2008US20080242731 Delivering a near neutral pH topical anesthetic agent in a mixture into a natural body cavity to cause a rapid onset anesthetic effect without precipitation of the anesthetic; use in uterine area; lidocaine for example
10/02/2008US20080242725 pharmaceutical ingredients susceptible to conversion to alternate polymorph forms are prepared by a process of wet granulation in which the ratios of active, fillers, and granulating liquid are controlled in order to avoid polymorphic interconversions
10/02/2008US20080242691 Aqueous Solution Preparation Containing Camptothecins
10/02/2008US20080242686 Pharmaceutical compositions of lavendustin
10/02/2008US20080242637 Binding efficiency;cyxicity; therapy for lung, colon, ovariers tumor
10/02/2008US20080242625 Nucleotide-Cochleate Compositions And Methods Of Use
10/02/2008US20080242614 Polypeptide containing valine or proline; therapy for infections
10/02/2008US20080241906 Shifting elution properties of viral protein in order to enhanced purification from solution
10/02/2008US20080241314 Compositions Of Polyvinylacetate and Vinylacetate-Vinyl Laurate Copolymer
10/02/2008US20080241261 Tablets utillizing polyvinylpyrrolidone finely dispersed in polyvinyl acetate; high dosage levels; applicable to drugs, nutraceuticals, vitamins, minerals, trace elements
10/02/2008US20080241259 Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof
10/02/2008US20080241251 Method of Producing Microparticles
10/02/2008US20080241244 Combining with such as potassium phosphate buffer solution containing sucrose, gelatin and ethylene oxide-propylene oxide copolymer; cooling, expanding then evaporation or sublimation drying; shelf life
10/02/2008US20080241243 Biodegradable fibrillar collagen matrix; sustained release; postsurgery pain control
10/02/2008US20080241236 Minocycline oral dosage forms for the treatment of acne
10/02/2008US20080241235 Controlled release carrier selected from hydroxypropyl methyl cellulose, hydroxypropyl cellulose, and polyvinylpyrrolidone; improved pharmacokinetics as compared to immediate-release minocycline hydrochloride; side effect reduction
10/02/2008US20080241224 Non-Polymeric Lipophilic Pharmaceutical Implant Compositions For Intraocular Use
10/02/2008US20080241222 Implanting the extended release, biodegradable implant containing dexamethasone directly into the vitreous of the eye; side effect reduction; macular degeneration
10/02/2008US20080241221 Extended therapeutic effect ocular implant treatments
10/02/2008US20080241220 Extended therapeutic effect ocular implant treatments
10/02/2008US20080241219 Implanting the extended release, biodegradable implant containing dexamethasone directly into the vitreous of the eye; side effect reduction; macular degeneration
10/02/2008US20080241216 Preparation Containing Active and/or Auxiliary Substances, With Controllable Release of Said Substances, As Well As Its Use and Manufacture
10/02/2008US20080241161 Liposome encapsulated antitumor immunoglobulin fusion for use in treatment of breast cell proliferative disorders
10/02/2008US20080241157 Nerve cell growth modulators (amphibodies)
10/02/2008US20080241123 self-assembly; made from one or more species selected from the group of carbon, silicon, a noble metal, silicon dioxide and titanium dioxide; for treatment of tumors or targeted drug delivery when a magnetic field or near-IR radiation is applied
10/02/2008US20080241105 Pretreatment with oncolytic virus
10/02/2008US20080241102 Nucleophile/biodrug cascades
10/02/2008US20080241093 A potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic
10/02/2008US20080241092 Administering a potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic
10/02/2008US20080241089 Oil-in-water dispersion/emulsion of a lipid or wax )melting point of >50 degrees C.), a nonionic oil-in-water emulsifier , a fatty ester as consistency regulator and/or water binder, oil, alkanol, water and active ingredient; rapid release; stability; spreadability; industrial scale; not too sticky
10/02/2008US20080241083 Artificial nail compositions and related methods
10/02/2008US20080241078 Compositions and methods for treating hair loss using c16-c20 aromatic tetrahydro prostaglandins
10/02/2008US20080241064 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
10/02/2008CA2684655A1 Oral pharmaceutical preparation for colon-specific delivery
10/02/2008CA2682490A1 Prompt nucleic acid delivery carrier composition
10/02/2008CA2682173A1 Solid fibrinogen preparation
10/02/2008CA2681766A1 Multivalent heterobifunctional polymers and methods of their use
10/02/2008CA2681570A1 Shortened purification process for the production of capsularstreptococcus pneumoniae polysaccharides
10/02/2008CA2681404A1 Fusion protein capable of degrading amyloid beta peptide
10/02/2008CA2681144A1 Cancer disease modifying antibody 010207-01 produced by hybridoma cell line ar51a630.3.
10/01/2008EP1975231A1 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
10/01/2008EP1975183A1 Tumour-specific recognition molecules
10/01/2008EP1975172A2 High affinity TGFß nucleic acid ligands and inhibitors
10/01/2008EP1974752A1 Subcellular targeting of therapeutic proteins
10/01/2008EP1974751A1 Formulations for non-steroidal anti-inflammatory drugs
10/01/2008EP1974742A1 A method for improving the manufacturing process of a tumour vaccine
10/01/2008EP1974741A1 Dried blood factor composition stabilised by trehalose
10/01/2008EP1974725A1 Sustained release preparation and method for production thereof
10/01/2008EP1974724A2 Oral preparations with good disintegration
10/01/2008EP1974721A1 Injectable sterile pharmaceutical composition with piperacillin sodium and tazobactam sodium as active principles
10/01/2008EP1973952A1 Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
10/01/2008EP1973947A2 Immunoconjugates with improved efficacy for the treatment of diseases
10/01/2008EP1973941A2 Compositions and methods for inhibiting viral adhesion
10/01/2008EP1973608A1 Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
10/01/2008EP1973573A2 Methods and compositions for expanding t regulatory cells
10/01/2008EP1973572A2 In vivo cell surface engineering
10/01/2008EP1973571A1 New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
10/01/2008EP1973570A1 Pharmaceutical formulations comprising dextran with molecular weight of 1.0-100kda and processes for their preparation
10/01/2008EP1973530A2 Gastric release pulse system for drug delivery
10/01/2008EP1973528A2 Sustained-release formulations of topiramate
10/01/2008EP1973525A1 Emulsion-containing medical articles
10/01/2008EP1973524A1 Concentrated liquid thyroid hormone composition
10/01/2008EP1973406A2 A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
10/01/2008EP1765162A4 Contrast agents for magnetic resonance imaging
1 ... 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 ... 1712